Michael Teifel
Impact in
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
Papers in
-
- Angiogenesis and VEGF in Cancer 7
- RNA Interference and Gene Delivery 5
- Oncology 7
- Cancer-related Molecular Pathways 4
- Co-authors
- Uwe Michaelis (12 shared papers)Marc Dellian (10 shared papers)Birgitta Sauer (9 shared papers)Peter Friedl (5 shared papers)Kurt Naujoks (5 shared papers)Martin Eichhorn (8 shared papers)B. Schulze (4 shared papers)Sebastian Strieth (8 shared papers)
In The Last Decade
Michael Teifel
37 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 97
- Biomaterials 499
- Pharmaceutical Science 70
- Molecular Biology 591
- Oncology 188
- Biomedical Engineering 287
Countries citing papers authored by Michael Teifel
This map shows the geographic impact of Michael Teifel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Teifel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Teifel more than expected).
Fields of papers citing papers by Michael Teifel
This network shows the impact of papers produced by Michael Teifel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Teifel. The network helps show where Michael Teifel may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Teifel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 275 | |
| 2 | Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. | 2003 | 172 |
| 3 | 2003 | 119 | |
| 4 | 2000 | 107 | |
| 5 | 2004 | 90 | |
| 6 | 2008 | 61 | |
| 7 | 1996 | 57 | |
| 8 | 2007 | 49 | |
| 9 | 1997 | 41 | |
| 10 | 2014 | 34 | |
| 11 | 2007 | 31 | |
| 12 | 2006 | 28 | |
| 13 | 2008 | 25 | |
| 14 | 2017 | 21 | |
| 15 | 2004 | 20 | |
| 16 | Establishment of a human placental endothelial cell line with extended life span after transfection with SV 40 T-antigens. | 1997 | 12 |
| 17 | 2013 | 11 | |
| 18 | 2021 | 10 | |
| 19 | 2005 | 9 | |
| 20 | 2014 | 8 |
About Michael Teifel
Michael Teifel is a scholar working on Molecular Biology, Oncology, Biomaterials, Biomedical Engineering and Cancer Research, having authored 37 papers that have together received 1.2k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (7 papers), Nanoparticle-Based Drug Delivery (6 papers), RNA Interference and Gene Delivery (5 papers), Cancer-related Molecular Pathways (4 papers), Nanoplatforms for cancer theranostics (4 papers), Cell Adhesion Molecules Research (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Click Chemistry and Applications (2 papers). The work is most often cited by research in Biomaterials (499 citations), Pharmaceutical Science (70 citations), Molecular Biology (591 citations), Oncology (188 citations) and Biomedical Engineering (287 citations). Michael Teifel has collaborated with scholars based in Germany, France and Hungary. Frequent co-authors include Uwe Michaelis, Marc Dellian, Birgitta Sauer, Peter Friedl, Kurt Naujoks, Martin Eichhorn, B. Schulze, Sebastian Strieth, Senat Krasnici and M. Schmitt‐Sody. Their work appears in journals such as Cancer Research, Bioorganic & Medicinal Chemistry Letters, International Journal of Cancer, Cancer Biology & Therapy and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.